Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.47 |
| ▸ | GHSR | Q92847 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648138 | 1.00 | FFAR1 (0.47) | FFAR1GHSRKDM4EAHCYKDM1A | |
| SCHEMBL4317069 | 0.77 | CHEK2 (0.52) | KDM4EKDM1AMEN1KMT2AHCRTR2 | |
| SCHEMBL4324225 | 0.76 | LTA4H (0.48) | FFAR1KDM1A | |
| SCHEMBL4324219 | 0.76 | LTA4H (0.48) | FFAR1KDM1A | |
| SCHEMBL2545927 | 0.76 | RIPK1 (0.46) | AHCYOPRD1USP30UCHL1 | |
| SCHEMBL938055 | 0.74 | ABHD6 (0.50) | KDM1A | |
| SCHEMBL938053 | 0.74 | ABHD6 (0.50) | KDM1A | |
| SCHEMBL27936838 | 0.74 | ABHD6 (0.50) | KDM1A | |
| SCHEMBL4308226 | 0.74 | PRMT5 (0.50) | FFAR1GHSRKDM4EAHCYKDM1A | |
| SCHEMBL4310678 | 0.74 | FFAR1 (0.46) | FFAR1GHSRAHCYKDM1AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | FFAR1 106/4885GHSR 72/4885KDM4E 1898/4885 |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | FFAR1 106/4885GHSR 72/4885KDM4E 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.